Which chemotherapeutic agent is linked with weight gain?

Aromatase inhibitors are known to be linked with weight gain, particularly in patients undergoing treatment for breast cancer. These agents work by blocking the aromatase enzyme, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. Since estrogen can influence body weight and fat distribution, the reduction of estrogen as a result of therapy with aromatase inhibitors can lead to an increase in fat mass and weight for some patients.

This phenomenon is often observed in postmenopausal women who are treated with aromatase inhibitors, as they may experience metabolic changes that include increased fat storage and alterations in energy balance. Furthermore, the impact of aromatase inhibitors extends beyond just weight gain; it may also lead to changes in body composition, particularly an increase in visceral fat, which can contribute to other health issues.

In contrast, medications such as metformin, acetaminophen, and ibuprofen are not typically associated with weight gain. Metformin is primarily used in diabetes management and is often linked with weight loss or weight neutrality. Acetaminophen and ibuprofen are non-opioid analgesics primarily used for pain and inflammation without any significant impact on weight. Therefore, understanding the specific effects of treatments on body